newsfilter
← Latest News
Business Wire·

Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2021

- Expanded Phase 2 data set continues to provide compelling rationale for move to registrational clinical program - - Bomedemstat demonstrated durable clinical improvement in patients with ET who failed at least one standard therapy (usually hydroxyu